Albireo Retained Earnings

Delisted . USA . 
Stock . Albireo Pharma
ALBODelisted Stock  USD 44.15  0.75  1.67%   
Albireo Pharma fundamentals help investors to digest information that contributes to Albireo Pharma's financial success or failures. It also enables traders to predict the movement of Albireo Stock. The fundamental analysis module provides a way to measure Albireo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Albireo Pharma stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
As of 22nd of March 2023, Accumulated Retained Earnings Deficit is likely to drop to about (277.9 M). In addition to that, Earnings Before Interest Taxes and Depreciation Amortization EBITDA is likely to drop to about (19.3 M).

Albireo Retained Earnings Analysis

Albireo Pharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
 2020 2021 2022 2023 (projected)
Revenues USD8.31 M40.58 M46.67 M50.35 M
Revenues8.31 M40.58 M46.67 M50.35 M
Retained Earnings 
 = 
Beginning RE + Income 
- 
Dividends 
More About Retained Earnings | All Equity Analysis

Current Albireo Pharma Retained Earnings

    
  (171.75 M)  
Most of Albireo Pharma's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Competition

Albireo Accumulated Retained Earnings Deficit

Accumulated Retained Earnings Deficit

(277.89 Million)

Albireo Pharma Accumulated Retained Earnings Deficit are very stable at the moment as compared to the past year. Albireo Pharma reported last year Accumulated Retained Earnings Deficit of (270.76 Million)
Based on the latest financial disclosure, Albireo Pharma has a Retained Earnings of (171.75 Million). This is 118.44% lower than that of the Biotechnology sector and 277.26% lower than that of the Health Care industry. The retained earnings for all United States stocks is 101.84% higher than that of the company.

Albireo Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.
Albireo Pharma is currently under evaluation in retained earnings category among related companies.

Albireo Pharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.
201820192020202120222023 (projected)
Net Income Per Employee(1.18 M)(1.14 M)(1.19 M)(261.77 K)(301.03 K)(324.8 K)
Revenue Per Employee326.67 K175.2 K92.06 K312.15 K358.97 K360.48 K
Average Assets199.19 M172.87 M240.71 M266.95 M307 M331.23 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(41.21 M)(57.29 M)(96.08 M)(19.82 M)(17.84 M)(19.25 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(41.21 M)(57.29 M)(96.08 M)(19.82 M)(17.84 M)(19.25 M)
Earnings before Tax(46.09 M)(62.72 M)(107.63 M)(34.03 M)(30.63 M)(33.04 M)
Average Equity142.23 M105.98 M148.89 M154.69 M177.89 M191.93 M
Enterprise Value120.02 M179.83 M446.4 M196.32 M225.76 M188.69 M
Free Cash Flow(26.85 M)(53.46 M)(101.11 M)(108.02 M)(97.22 M)(99.78 M)
Invested Capital(8.5 M)(2.96 M)1.41 M1.34 M1.54 M1.66 M
Invested Capital Average(5.73 M)(3.27 M)2.73 M(872 K)(784.8 K)(846.76 K)
Market Capitalization293.62 M322.49 M715.59 M449 M516.35 M557.11 M
Tangible Asset Value168.21 M147.81 M268.35 M284.79 M327.51 M353.37 M
Working Capital154.82 M122.88 M236.58 M223.58 M257.12 M277.42 M

Albireo Fundamentals

Return On Equity(0.93) %
Return On Asset(0.25) %
Profit Margin(2.29) %
Operating Margin(2.15) %
Current Valuation259.98 M
Shares Outstanding20.74 M
Shares Owned by Insiders3.60 %
Shares Owned by Institutions96.40 %
Number of Shares Shorted553.91 K
Price to Earning(4.16) X
Price to Book4.30 X
Price to Sales7.35 X
Revenue40.58 M
Gross Profit39.22 M
EBITDA(19.82 M)
Net Income(34.03 M)
Cash and Equivalents180.97 M
Cash per Share9.23 X
Total Debt10 M
Debt to Equity0.18 %
Current Ratio4.49 X
Book Value Per Share4.84 X
Cash Flow from Operations(107.56 M)
Short Ratio0.86 X
Earnings Per Share(6.66) X
Target Price44.0
Number of Employees130
Beta1.04
Market Capitalization915.89 M
Total Asset302.05 M
Retained Earnings(171.75 M)
Working Capital26.76 M
Current Asset28.84 M
Current Liabilities2.07 M
Z Score54.6
Net Asset302.05 M

About Albireo Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2023
Accumulated Retained Earnings Deficit-270.8 M-277.9 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-17.8 M-19.3 M
Earnings before Tax-30.6 M-33 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-0.87ABIOARCA Biopharma Fiscal Quarter End 31st of March 2023 PairCorr
-0.71ACERAcer Therapeutics Financial Report 15th of May 2023 PairCorr
-0.59AADIAadi Bioscience Earnings Call This WeekPairCorr
-0.54ACGNAceragen Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Valuation
Check real value of public entities based on technical and fundamental data


 
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY